40+ Virtual Presentations from Top Biopharma at PEGS Europe
Novel Applications of Ribosome Display for Therapeutic and Diagnostic mAb DiscoveryMark Austin, Research Scientist, AstraZeneca
They Must Be Compatible: Mutual Interaction Phenomena between Protein Formulation and Siliconized/Silicone-Free Syringe Packaging Materials with an Effect on Functionality and StabilityKaroline B. Bechtold-Peters, PhD, Senior Strategy & Technology Leader, Pharmaceuticals & Biopharma Process, Novartis Pharma AG
Targeting Bispecific Biologics to Disease TissuesLorenzo Benatuil, PhD, Senior Principal Research Scientist & Head, Biologics, AbbVieExploring the Non-Ideality of High-Concentration Biopharmaceutical Formulations by AUCAlexander Bepperling, PhD, Lab Head, Biophysical Characterisation II, Technical R&D/Technical Development Biosimilars, Novartis Global Drug DevelopmentMim8: Development of a Next-Generation Factor VIII-Mimetic Bispecific AntibodyJais R. Bjelke, PhD, Senior Scientist, Global Research, Novo Nordisk ASBispecific Antibodies – Next-Generation Molecules & ApplicationsUlrich Brinkmann, PhD, Expert Scientist, Pharma Research & Early Development, Roche Innovation Center ZurichLarge-Scale NBEs Continuous Manufacturing: From Concept to RealityJohan Chami, Scientist, Drug Substance Clinical Operations, Global Healthcare Operations, Biotech Process Sciences, Merck SeronoDetermining Binding Affinities of Therapeutic Antibodies Targeting Transmembrane ProteinsTony Christopeit, PhD, Research Scientist, Pharma Research & Early Development, Roche Diagnostics GmbHOptimising C7 Antibodies for High Affinity and DevelopabilitySusannah Davis, Scientific Leader, BioPharm, GlaxoSmithKlineAntibody Discovery Is More than Just BindersRuud M. De Wildt, PhD, Director & Biopharm R&D Head, Lead Discovery, GlaxoSmithKlineEngineering the Next Generation of TherapeuticsJohn Delaney, PhD, Director, Research Technologies and Collaborations, AmgenDevelopment and Application of Screening Assays to Predict Aggregation upon Long- Term StorageFabian Dingfelder, PhD, Industrial Postdoc, Biophysics, Novo Nordisk ASTumor-Conditional Anti-CTLA4 Uncouples Antitumor Efficacy from Immunotherapy- Related ToxicityFeng Dong, PhD, Principal Research Scientist II, Foundational Immunology, AbbVie Cambridge Research CenterChallenges in Characterization and Developability Assessments of Multispecific AntibodiesMelanie Fischer, PhD, Section Head Assays and Analytics, Biologics Research, SanofiMolecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy, Aimovig (Erenumab)Fernando Garces, PhD, Senior Scientist and Group Lead, Protein Engineering, Therapeutics Discovery, Amgen, Inc.A Novel Approach in Middle-Down Biologics CharacterizationFrancois Griaud, PhD, Functional Lead & Principal Scientist, Analytical Development & Characterization, Novartis Pharma AGImmune Modulation by Targeted Antigen Delivery to and Metabolic Manipulation of Antigen-Presenting Cells (APCs)Subramanya Hegde, PhD, Principal Research Scientist II, AbbVieFrom Glassware to Software: Better Understanding of Chemical Degradation Mechanisms by Physics-Based SimulationsSaeed Izadi, PhD, Scientist, Early Stage Pharmaceutical Development, Genentech, Inc.Targeting Pro-Tumor Inflammation Via the Inflammasome PathwayPushpa Jayaraman, PhD, Senior Investigator I, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical ResearchChemical Modifications in Biotherapeutic Proteins and Their Impact on HOS and FunctionSambit R. Kar, PhD, Principal Scientist & Head, Biophysics Center of Excellence, Bristol Myers Squibb Co.BiTE® Antibody Constructs for the Treatment of CancerRoman Kischel, MD, Director, Research & Early Development Lead, Oncology, Amgen Research Munich GmbHPD1-X: Targeting PD-1 with Bispecific AgentsChristian Klein, PhD, Cancer Immunotherapy Discovery, Roche Pharma Research & Early Development, Roche Innovation Center ZurichInclusion Body Processing: A REAL Black Box Case StudyDaniel Kronberger, Head, Downstream Pilot, Process Science, Boehringer Ingelheim RCV GmbH & Co. KGmAbs vs. Bugs: Antibody Therapies for Infectious DiseaseSteve Martin, PhD, Vice President, Biopharm Discovery, GlaxoSmithKlineAllosteric Anti-Tryptase Antibodies for the Treatment of Mast-Cell Mediated Severe AsthmaHenry Maun, PhD, Associate Director, External Innovation, RochePresence of a Positive Charge Cluster on Fc-fusion of Mouse LIGHT Impacts Its Exposure and in vivo Activity in MiceAyse Meric Ovacik, PhD, Scientist, Developmental Sciences, Genentech, Inc.
Oncolytic Virus and Antibody-Drug Conjugate-Based Therapeutic Combinations: Different Modalities – Common ThemesJutta Petschenka, Principal Scientist, Boehringer Ingelheim Pharma GmbH & Co. KGRapid Discovery of Anti-Viral Antibodies and Development as Gene Therapies for Pandemic PreventionSarav Rajan, PhD, Senior Scientist, AstraZenecaHuman Monoclonal Antibodies for Prevention and Therapy of Covid-19Rino Rappuoli, PhD, Chief Scientist & Head, External R&D, GSK VaccinesIdentification of HCPs Inducing Particle Formation during Protein Stability TestingVeronika Reisinger, PhD, Lab Head, Physico Chemical Characterization, Novartis AGAUC Characterization of Empty, Partial, and Full AAV ParticlesChris Rogers, Senior Scientist, Allergan BiologicsChallenges of the Day-to-Day Lab-Scale Protein Production and How to Overcome ThemPeter Schmidt, PhD, Director, Recombinant Technologies, R&D, CSL Behring GmbHRapid Identification of Highly Potent Fully Human Anti-CCR-1 Antagonist mAbsMartin Scott, PhD, Scientific Leader & Associate Fellow, GlaxoSmithKlineSmall-Angle Neutron and X-Ray Scattering: Emerging Biophysical Tools for Frozen and Freeze-Dried BiologicalsEvgenyi Y. Shalaev, PhD, Research Investigator, Pharmaceutical Development, Allergan, Inc.Combinatorial Approaches to Enhance Bispecific Anti-Tumor EfficacyEric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.Predicting Solution Behavior during Developability ScreeningCharles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi GroupNew Factor VIII Function-Mimetic Bispecific Antibodies Engineered from Emicizumab for Further Improving the Treatment of Haemophilia AYuri Teranishi, Research Scientist, Discovery Research, Chugai Pharmaceutical Co., Ltd.From Formulation Screening to Early ManufacturingBernhard Valldorf, PhD, Principal Scientist & Lab Head, Formulation Development, EMD SeronoIn Pursuit of Quality Molecules: Early Biophysical Characterization Tools for the Prediction of in vivo StabilitySathya Venkataramani, PhD, Associate Director, Biophysics, BDS, Janssen BiotherapeuticsCell Line Development for Biologics R&DBernd Voedisch, PhD, Principal Scientist II, Novartis Pharma AGDevelopment of Novel Native LC-MS Methods and Solutions for the Characterization of mAbs and Related ProductsShunhai Wang, PhD, Senior Staff Scientist, Analytical Chemistry, Regeneron Pharmaceuticals Inc.Modulating the Receptor Binding Site of Immunoligands for Enhanced Potency and EfficacyStefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA